Wellmune, a natural immune health ingredient for foods, beverages and supplements, helped modulate immune responses to improve overall health and quality of life, according to clinical results published online in the peer-reviewed journal Food Science & Nutrition.
Wellmune modulated immune responses, as measured by a significantly significant reduction in allergy symptoms in people with ragweed allergies, according to researchers. An estimated 40 to 50 million Americans are affected by allergies, with ragweed a leading cause of seasonal allergy symptoms including nasal congestion, sneezing, itchy eyes and difficulty breathing. Allergy symptoms are caused by an immune system overreaction to ragweed pollen.
The placebo-controlled, double-blinded study of 48 healthy people who were subjected to high pollen counts demonstrated statistically significant (p<0.05):
- Reductions in overall symptoms and severity
- Reductions in key nasal and eye-related allergy symptoms
- Improvement on the Quality of Life Index, a scientifically validated tool for measuring how participants rate their overall sense of wellness.
Wellmune, a proprietary baker’s yeast beta glucan, activates innate immune cells that are part of the body’s natural defenses without over-stimulating the immune system. In this study, Wellmune was found to modulate the immune system when less of an immune response was needed.
The results of this study are consistent with numerous previous peer-reviewed, published studies demonstrating that Wellmune can safely boost the immune system to keep the body healthy.
“A daily regimen including all-natural Wellmune is well-documented to safely support immune health, a key contributor to overall health and well-being,” said Richard G. Mueller, chief executive officer of the Wellmune brand. “This study shows that Wellmune can effectively modulate immune responses to help the immune system to achieve balance that is important to staying healthy.”
The randomized, placebo-controlled, double-blind study included self-described “moderate” ragweed allergy sufferers. Forty-eight healthy subjects were equally divided (31 female, 17 male; 39± 13 years of age) into two groups. One group consumed a placebo while the other a 250 mg serving of Wellmune daily for four weeks during September/October 2011 in an area of southeast Ohio with high pollen counts. Participants completed allergy surveys including the validated Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) to assess differences in allergy symptoms.